In Vitro and In Vivo Activities of CS-758 (R-120758), a New Triazole Antifungal Agent
AUTOR(ES)
Kamai, Yasuki
FONTE
American Society for Microbiology
RESUMO
The activity of CS-758 (R-120758), a new triazole antifungal agent, was evaluated and compared with those of fluconazole, itraconazole, and amphotericin B in vitro and with those of fluconazole and itraconazole in vivo. CS-758 exhibited potent in vitro activity against clinically important fungi. The activity of CS-758 against Candida spp. was superior to that of fluconazole and comparable or superior to those of itraconazole and amphotericin B. CS-758 retained potent activity against Candida albicans strains with low levels of susceptibility to fluconazole (fluconazole MIC, 4 to 32 μg/ml). Against Aspergillus spp. and Cryptococcus neoformans, the activity of CS-758 was at least fourfold superior to those of the other drugs tested. CS-758 also exhibited potent in vivo activity against murine systemic infections caused by C. albicans, C. neoformans, Aspergillus fumigatus, and Aspergillus flavus. The 50% effective doses against these infections were 0.41 to 5.0 mg/kg of body weight. These results suggest that CS-758 may be useful in the treatment of candidiasis, cryptococcosis, and aspergillosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127071Documentos Relacionados
- In vitro and in vivo antifungal activities of D0870, a new triazole agent.
- In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida
- T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.
- In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R126638
- In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.
